COMP <GO>
IPSC vs LXEO // EV/EBITDA & P/E VALUATION
Century Therapeutics Inc. (NASDAQ) VS. Lexeo Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: IPSC 3
— LXEO 1
■ METRIC PARITY
LAST: $1.46 (-2.67%) • MKT CAP: $264.4M
valuation
—
LAST: $3.06 (-2.24%) • MKT CAP: $251.1M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IPSC VS. LXEO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IPSC | LXEO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -14.10% | -35.00% | +20.90 | IPSC | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -15.80% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -8.80% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 2/9 | +1.00 | IPSC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.7 | 48.3 | -3.55 | LXEO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $264.4M | $251.1M | $13.3M | IPSC | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IPSC REV | LXEO REV | IPSC GROSS % | LXEO GROSS % | IPSC FCF | LXEO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $109.2M | $0 | — | — | -$104.7M | -$99.0M |
| FY 2024 | $6.6M | $0 | — | — | -$110.3M | -$81.6M |
| FY 2023 | $2.2M | $0 | — | — | -$88.3M | -$59.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IPSC // BETA —
LXEO // BETA —